Using Insulin to Treat Poorly Controlled Type 2 Diabetes in 2020
- 16 June 2020
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA
- Vol. 323 (23), 2419-2420
- https://doi.org/10.1001/jama.2020.1303
Abstract
This JAMA Insights Clinical Update reviews indications and timing of insulin therapy for management of type 2 diabetes, emphasizing the likely benefit of its use as first-line therapy in patients with HbA(1c)levels less than 9.0%.This publication has 7 references indexed in Scilit:
- Comment on Jakubowicz et al. Reduction in Glycated Hemoglobin and Daily Insulin Dose Alongside Circadian Clock Upregulation in Patients With Type 2 Diabetes Consuming a Three-Meal Diet: A Randomized Clinical Trial. Diabetes Care 2019;42:2171-2180Diabetes Care, 2020
- Predictors of Insulin Initiation in Patients with Type 2 Diabetes: An Analysis of the Look AHEAD Randomized TrialJournal of General Internal Medicine, 2018
- Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal InsulinDiabetes Therapy, 2018
- Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patientsDiabetes, Obesity and Metabolism, 2011
- Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trialThe Lancet, 2008
- Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational studyBMJ, 2000
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998